WallStSmart

Henry Schein Inc (HSIC)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 480% more annual revenue ($13.38B vs $2.31B). HSIC leads profitability with a 3.0% profit margin vs -9.0%. HSIC earns a higher WallStSmart Score of 52/100 (C-).

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 2.71

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HSICUndervalued (+64.5%)

Margin of Safety

+64.5%

Fair Value

$229.97

Current Price

$70.82

$159.15 discount

UndervaluedFair: $229.97Overvalued

Intrinsic value data unavailable for NTRA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

NTRA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
39.8%10/10

Revenue surging 39.8% year-over-year

Areas to Watch

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.614/10

Expensive relative to growth rate

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.023/10

Elevated debt levels

NTRA4 concerns · Avg: 2.8/10
Price/BookValuation
15.8x4/10

Trading at 15.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-14.3%2/10

ROE of -14.3% — below average capital efficiency

Profit MarginProfitability
-9.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, EPS Growth, Profit Margin. Thin 3.0% margins leave little buffer for downturns.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

HSIC profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.57 — expect wider price swings.

NTRA is growing revenue faster at 39.8% — sustainability is the question.

NTRA generates stronger free cash flow (38M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (52/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?